



: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F : SCHI.0000022830

UHID/MR No Visit ID

: SCHIOPV34457

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : hffdgujhg Collected

: 03/Aug/2024 05:11PM

Received Reported : 03/Aug/2024 05:38PM : 03/Aug/2024 07:25PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

PERIPHERAL SMEAR, WHOLE BLOOD EDTA

Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology SIN No:BED240203993



Page 1 of 13





: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F

UHID/MR No Visit ID

: SCHI.0000022830

Ref Doctor

: SCHIOPV34457

Emp/Auth/TPA ID

: Dr.SELF : hffdgujhg Collected

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 05:38PM

Reported

Status

: 03/Aug/2024 07:25PM

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
HEMOGRAM , WHOLE BLOOD EDTA				
HAEMOGLOBIN	13.4	g/dL	12-15	CYANIDE FREE COLOUROMETER
PCV	41.20	%	40-50	PULSE HEIGHT AVERAGE
RBC COUNT	6.03	Million/cu.mm	3.8-4.8	Electrical Impedence
MCV	68.4	fL	83-101	Calculated
MCH	22.2	pg	27-32	Calculated
MCHC	32.4	g/dL	31.5-34.5	Calculated
R.D.W	17.2	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	8,250	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT	(DLC)			
NEUTROPHILS	61.7	%	40-80	Electrical Impedance
LYMPHOCYTES	29.4	%	20-40	Electrical Impedance
EOSINOPHILS	2.8	%	1-6	Electrical Impedance
MONOCYTES	5.5	%	2-10	Electrical Impedance
BASOPHILS	0.6	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	5090.25	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	2425.5	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	231	Cells/cu.mm	20-500	Calculated
MONOCYTES	453.75	Cells/cu.mm	200-1000	Calculated
BASOPHILS	49.5	Cells/cu.mm	0-100	Calculated
Neutrophil lymphocyte ratio (NLR)	2.1		0.78- 3.53	Calculated
PLATELET COUNT	193000	cells/cu.mm	150000-410000	IMPEDENCE/MICROSCOPY
ERYTHROCYTE SEDIMENTATION RATE (ESR)	08	mm at the end of 1 hour	0-20	Modified Westergren
PERIPHERAL SMEAR				

RBCs ARE NORMOCYTIC NORMOCHROMIC.

TLC, DLC WITHIN NORMAL LIMIT. NO IMMATURE CELLS ARE SEEN. PLATELETS ARE ADEQUATE.

Page 2 of 13



Dr. SHWETA GUPTA MBBS, MD (Pathology) Consultant Pathology SIN No:BED240203993





: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F : SCHI.0000022830

UHID/MR No Visit ID

: SCHIOPV34457

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : hffdgujhg

Collected

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 05:38PM

Reported

: 03/Aug/2024 07:25PM

Status : Final Report Sponsor Name : ARCOFEMI F

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

NO HEMOPARASITES SEEN

Page 3 of 13







: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F

UHID/MR No Visit ID : SCHI.0000022830

Ref Doctor

: SCHIOPV34457 : Dr.SELF

Emp/Auth/TPA ID

: hffdgujhg

Collected

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 05:38PM

Reported

: 03/Aug/2024 09:56PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method			
BLOOD GROUP ABO AND RH FACTOR , WHOLE BLOOD EDTA							
BLOOD GROUP TYPE	В			Forward & Reverse Grouping with Slide/Tube Aggluti			
Rh TYPE	POSITIVE			Forward & Reverse Grouping with Slide/Tube Agglutination			

Page 4 of 13







: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F

UHID/MR No Visit ID

: SCHI.0000022830

Ref Doctor

: SCHIOPV34457 : Dr.SELF

: hffdgujhg

Emp/Auth/TPA ID

Collected

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 06:30PM

Reported Status

: 03/Aug/2024 07:14PM

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GLUCOSE, FASTING, NAF PLASMA	101	mg/dL	70-100	GOD - POD

Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

Page 5 of 13











: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F

UHID/MR No

: SCHI.0000022830

Visit ID

: SCHIOPV34457

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : hffdgujhg Collected

Status

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 07:44PM

Reported

: 03/Aug/2024 10:15PM

Sponsor Name

: Final Report

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
HBA1C (GLYCATED HEMOGLOBIN),	WHOLE BLOOD EDTA			
HBA1C, GLYCATED HEMOGLOBIN	5.7	%		HPLC
ESTIMATED AVERAGE GLUCOSE (eAG)	117	mg/dL		Calculated

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %
NON DIABETIC	<5.7
PREDIABETES	5.7 - 6.4
DIABETES	≥ 6.5
DIABETICS	
EXCELLENT CONTROL	6 – 7
FAIR TO GOOD CONTROL	7 - 8
UNSATISFACTORY CONTROL	8 - 10
POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic

Control by American Diabetes Association guidelines 2023.

- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control

A: HbF >25%

B: Homozygous Hemoglobinopathy.

(Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 6 of 13



Dr Nidhi Sachdev M.B.B.S, MD(Pathology) Consultant Pathologist

SIN No:EDT240083866





: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F

UHID/MR No

: SCHI.0000022830

Visit ID Ref Doctor : SCHIOPV34457

Emp/Auth/TPA ID

: Dr.SELF : hffdgujhg Collected

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 06:28PM

Reported

Status

: 03/Aug/2024 07:26PM

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method			
LIPID PROFILE , SERUM							
TOTAL CHOLESTEROL	128	mg/dL	<200	CHE/CHO/POD			
TRIGLYCERIDES	80	mg/dL	<150	Enzymatic			
HDL CHOLESTEROL	47	mg/dL	>40	CHE/CHO/POD			
NON-HDL CHOLESTEROL	81	mg/dL	<130	Calculated			
LDL CHOLESTEROL	65	mg/dL	<100	Calculated			
VLDL CHOLESTEROL	16	mg/dL	<30	Calculated			
CHOL / HDL RATIO	2.72		0-4.97	Calculated			
ATHEROGENIC INDEX (AIP)	0.02		<0.11	Calculated			

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

Measurements in the same patient can show physiological and analytical variations.

NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.

Page 7 of 13



SIN No:SE04800630





: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F

UHID/MR No

: SCHI.0000022830

Visit ID Ref Doctor : SCHIOPV34457

Emp/Auth/TPA ID

: Dr.SELF : hffdgujhg Collected

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 06:28PM

Reported

Status

: 03/Aug/2024 07:26PM

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
LIVER FUNCTION TEST (LFT), SERUM				
BILIRUBIN, TOTAL	0.30	mg/dL	0.20-1.30	DIAZO METHOD
BILIRUBIN CONJUGATED (DIRECT)	0.10	mg/dL	0.0-0.3	Calculated
BILIRUBIN (INDIRECT)	0.20	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	12	U/L	<35	Visible with P-5-P
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	26.0	U/L	14-36	UV with P-5-P
AST (SGOT) / ALT (SGPT) RATIO (DE RITIS)	2.2		<1.15	Calculated
ALKALINE PHOSPHATASE	96.00	U/L	38-126	p-nitrophenyl phosphate
PROTEIN, TOTAL	6.90	g/dL	6.3-8.2	Biuret
ALBUMIN	4.50	g/dL	3.5 - 5	Bromocresol Green
GLOBULIN	2.40	g/dL	2.0-3.5	Calculated
A/G RATIO	1.87		0.9-2.0	Calculated

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin) Common patterns seen:

- 1. Hepatocellular Injury:
- *AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal *ALT – Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI. Disproportionate increase in AST, ALT compared with ALP. AST: ALT (ratio) – In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.
- 2. Cholestatic Pattern:
- *ALP Disproportionate increase in ALP compared with AST, ALT. ALP elevation also seen in pregnancy, impacted by age *Bilirubin elevated- predominantly direct, To establish the hepatic origin correlation with elevated GGT helps. and sex.
- 3. Synthetic function impairment:
- *Albumin-Liver disease reduces albumin levels, Correlation with PT (Prothrombin Time) helps.
- 4. Associated tests for assessment of liver fibrosis Fibrosis-4 and APRI Index.

Page 8 of 13



Dr. SHWETA GUPTA MBBS, MD (Pathology) Consultant Pathology SIN No:SE04800630





: Mrs.RAJASHREE LAXMI

Age/Gender

Emp/Auth/TPA ID

: 37 Y 6 M 0 D/F

UHID/MR No Visit ID

: SCHI.0000022830

Ref Doctor

: Dr.SELF

: SCHIOPV34457

: hffdgujhg

Collected

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 06:28PM

Reported Status

: 03/Aug/2024 07:26PM

Sponsor Name

: Final Report : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology SIN No:SE04800630





: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F

UHID/MR No

: SCHI.0000022830

Visit ID Ref Doctor : SCHIOPV34457

Emp/Auth/TPA ID

: Dr.SELF : hffdgujhg Collected

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 06:28PM

Reported

: 03/Aug/2024 07:26PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED


DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method			
RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT), SERUM							
CREATININE	0.70	mg/dL	0.5-1.04	Creatinine amidohydrolase			
UREA	14.10	mg/dL	15-36	Urease			
BLOOD UREA NITROGEN	6.6	mg/dL	8.0 - 23.0	Calculated			
URIC ACID	4.70	mg/dL	2.5-6.2	Uricase			
CALCIUM	8.00	mg/dL	8.4 - 10.2	Arsenazo-III			
PHOSPHORUS, INORGANIC	4.00	mg/dL	2.5-4.5	PMA Phenol			
SODIUM	139	mmol/L	135-145	Direct ISE			
POTASSIUM	5.2	mmol/L	3.5-5.1	Direct ISE			
CHLORIDE	108	mmol/L	98 - 107	Direct ISE			
PROTEIN, TOTAL	6.90	g/dL	6.3-8.2	Biuret			
ALBUMIN	4.50	g/dL	3.5 - 5	Bromocresol Green			
GLOBULIN	2.40	g/dL	2.0-3.5	Calculated			
A/G RATIO	1.88		0.9-2.0	Calculated			

Page 10 of 13









: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F

UHID/MR No Visit ID

: SCHI.0000022830

Ref Doctor

: SCHIOPV34457

Emp/Auth/TPA ID

: Dr.SELF : hffdgujhg Collected

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 06:28PM

Reported

Status

: 03/Aug/2024 07:26PM

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GAMMA GLUTAMYL TRANSPEPTIDASE (GGT) , SERUM	10.00	U/L	12-43	Glyclyclycine Nitoranalide

Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology

SIN No:SE04800630

Page 11 of 13







: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F

UHID/MR No Visit ID : SCHI.0000022830

Ref Doctor

: SCHIOPV34457 : Dr.SELF

Emp/Auth/TPA ID : hffdgujhg

Collected

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 07:44PM

Reported

: 03/Aug/2024 09:06PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method		
THYROID PROFILE TOTAL (T3, T4, TSH) , SERUM						
TRI-IODOTHYRONINE (T3, TOTAL)	1.02	ng/mL	0.87-1.78	CLIA		
THYROXINE (T4, TOTAL)	9.4	μg/dL	5.48-14.28	CLIA		
THYROID STIMULATING HORMONE (TSH)	3.136	μIU/mL	0.38-5.33	CLIA		

Comment:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 - 3.0

- **1.** TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- **2.** TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- **3.** Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.
- **4.** Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	T3	T4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes

Page 12 of 13

Dr.Tanish Mandal M.B.B.S,M.D(Pathology) Consultant Pathologist SIN No:SPL24128160









: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F : SCHI.0000022830

UHID/MR No Visit ID

. 00111.0000002200

Ref Doctor

: SCHIOPV34457

Emp/Auth/TPA ID

: Dr.SELF : hffdgujhg Collected

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 07:44PM

Reported

: 03/Aug/2024 09:06PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY


ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma	
------	------	------	------	--	--

*** End Of Report ***

Page 13 of 13









: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F : SCHI.0000022830

UHID/MR No Visit ID

: SCHIOPV34457

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : hffdgujhg Collected

: 03/Aug/2024 05:11PM

Received Reported : 03/Aug/2024 05:38PM : 03/Aug/2024 07:25PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

PERIPHERAL SMEAR, WHOLE BLOOD EDTA

Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology SIN No:BED240203993



Page 1 of 13





: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F

UHID/MR No

: SCHI.0000022830

Visit ID

: SCHIOPV34457

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : hffdgujhg Collected

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 05:38PM

Reported

Status

: 03/Aug/2024 07:25PM

Sponsor Name

: Final Report

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
HEMOGRAM , WHOLE BLOOD EDTA				
HAEMOGLOBIN	13.4	g/dL	12-15	CYANIDE FREE COLOUROMETER
PCV	41.20	%	40-50	PULSE HEIGHT AVERAGE
RBC COUNT	6.03	Million/cu.mm	3.8-4.8	Electrical Impedence
MCV	68.4	fL	83-101	Calculated
MCH	22.2	pg	27-32	Calculated
MCHC	32.4	g/dL	31.5-34.5	Calculated
R.D.W	17.2	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	8,250	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT	(DLC)			
NEUTROPHILS	61.7	%	40-80	Electrical Impedance
LYMPHOCYTES	29.4	%	20-40	Electrical Impedance
EOSINOPHILS	2.8	%	1-6	Electrical Impedance
MONOCYTES	5.5	%	2-10	Electrical Impedance
BASOPHILS	0.6	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	5090.25	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	2425.5	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	231	Cells/cu.mm	20-500	Calculated
MONOCYTES	453.75	Cells/cu.mm	200-1000	Calculated
BASOPHILS	49.5	Cells/cu.mm	0-100	Calculated
Neutrophil lymphocyte ratio (NLR)	2.1		0.78- 3.53	Calculated
PLATELET COUNT	193000	cells/cu.mm	150000-410000	IMPEDENCE/MICROSCOPY
ERYTHROCYTE SEDIMENTATION RATE (ESR)	08	mm at the end of 1 hour	0-20	Modified Westergren
PERIPHERAL SMEAR				

RBCs ARE NORMOCYTIC NORMOCHROMIC.

TLC, DLC WITHIN NORMAL LIMIT. NO IMMATURE CELLS ARE SEEN. PLATELETS ARE ADEQUATE.

Page 2 of 13



Dr. SHWETA GUPTA MBBS, MD (Pathology) Consultant Pathology SIN No:BED240203993





: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F : SCHI.0000022830

UHID/MR No Visit ID

: SCHIOPV34457

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : hffdgujhg

Collected

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 05:38PM

Reported

: 03/Aug/2024 07:25PM

Status : Final Report Sponsor Name : ARCOFEMI F

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

NO HEMOPARASITES SEEN

Page 3 of 13







: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F

UHID/MR No

: SCHI.0000022830

Visit ID Ref Doctor : SCHIOPV34457

Emp/Auth/TPA ID

: Dr.SELF : hffdgujhg Collected

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 05:38PM

Reported

: 03/Aug/2024 09:56PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
BLOOD GROUP ABO AND RH FACTOR	R, WHOLE BLOOD EDTA		<u>'</u>	<u>'</u>
BLOOD GROUP TYPE	В			Forward & Reverse Grouping with Slide/Tube Aggluti
Rh TYPE	POSITIVE			Forward & Reverse Grouping with Slide/Tube Agglutination

Page 4 of 13









: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F

UHID/MR No Visit ID

: SCHI.0000022830

Ref Doctor

: SCHIOPV34457 : Dr.SELF

: hffdgujhg

Emp/Auth/TPA ID

Collected

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 06:30PM

Reported Status

: 03/Aug/2024 07:14PM

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GLUCOSE, FASTING, NAF PLASMA	101	mg/dL	70-100	GOD - POD

Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

Page 5 of 13











: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F

UHID/MR No

: SCHI.0000022830

Visit ID

: SCHIOPV34457

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : hffdgujhg Collected

Status

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 07:44PM

Reported

: 03/Aug/2024 10:15PM

Sponsor Name

: Final Report

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
HBA1C (GLYCATED HEMOGLOBIN),	WHOLE BLOOD EDTA			
HBA1C, GLYCATED HEMOGLOBIN	5.7	%		HPLC
ESTIMATED AVERAGE GLUCOSE (eAG)	117	mg/dL		Calculated

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %
NON DIABETIC	<5.7
PREDIABETES	5.7 - 6.4
DIABETES	≥ 6.5
DIABETICS	
EXCELLENT CONTROL	6 – 7
FAIR TO GOOD CONTROL	7 - 8
UNSATISFACTORY CONTROL	8 - 10
POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic

Control by American Diabetes Association guidelines 2023.

- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control

A: HbF >25%

B: Homozygous Hemoglobinopathy.

(Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 6 of 13



Dr Nidhi Sachdev M.B.B.S, MD(Pathology) Consultant Pathologist

SIN No:EDT240083866





: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F

UHID/MR No

: SCHI.0000022830

Visit ID Ref Doctor : SCHIOPV34457

Emp/Auth/TPA ID

: Dr.SELF : hffdgujhg Collected

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 06:28PM

Reported

Status

: 03/Aug/2024 07:26PM

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method				
LIPID PROFILE , SERUM								
TOTAL CHOLESTEROL	128	mg/dL	<200	CHE/CHO/POD				
TRIGLYCERIDES	80	mg/dL	<150	Enzymatic				
HDL CHOLESTEROL	47	mg/dL	>40	CHE/CHO/POD				
NON-HDL CHOLESTEROL	81	mg/dL	<130	Calculated				
LDL CHOLESTEROL	65	mg/dL	<100	Calculated				
VLDL CHOLESTEROL	16	mg/dL	<30	Calculated				
CHOL / HDL RATIO	2.72		0-4.97	Calculated				
ATHEROGENIC INDEX (AIP)	0.02		<0.11	Calculated				

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

Measurements in the same patient can show physiological and analytical variations.

NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.

Page 7 of 13



SIN No:SE04800630





: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F

UHID/MR No

: SCHI.0000022830

Visit ID Ref Doctor : SCHIOPV34457

Emp/Auth/TPA ID

: Dr.SELF : hffdgujhg Collected

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 06:28PM

Reported

Status

: 03/Aug/2024 07:26PM

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method				
LIVER FUNCTION TEST (LFT), SERUM								
BILIRUBIN, TOTAL	0.30	mg/dL	0.20-1.30	DIAZO METHOD				
BILIRUBIN CONJUGATED (DIRECT)	0.10	mg/dL	0.0-0.3	Calculated				
BILIRUBIN (INDIRECT)	0.20	mg/dL	0.0-1.1	Dual Wavelength				
ALANINE AMINOTRANSFERASE (ALT/SGPT)	12	U/L	<35	Visible with P-5-P				
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	26.0	U/L	14-36	UV with P-5-P				
AST (SGOT) / ALT (SGPT) RATIO (DE RITIS)	2.2		<1.15	Calculated				
ALKALINE PHOSPHATASE	96.00	U/L	38-126	p-nitrophenyl phosphate				
PROTEIN, TOTAL	6.90	g/dL	6.3-8.2	Biuret				
ALBUMIN	4.50	g/dL	3.5 - 5	Bromocresol Green				
GLOBULIN	2.40	g/dL	2.0-3.5	Calculated				
A/G RATIO	1.87		0.9-2.0	Calculated				

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin) Common patterns seen:

- 1. Hepatocellular Injury:
- *AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal *ALT – Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI. Disproportionate increase in AST, ALT compared with ALP. AST: ALT (ratio) – In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.
- 2. Cholestatic Pattern:
- *ALP Disproportionate increase in ALP compared with AST, ALT. ALP elevation also seen in pregnancy, impacted by age *Bilirubin elevated- predominantly direct, To establish the hepatic origin correlation with elevated GGT helps. and sex.
- 3. Synthetic function impairment:
- *Albumin-Liver disease reduces albumin levels, Correlation with PT (Prothrombin Time) helps.
- 4. Associated tests for assessment of liver fibrosis Fibrosis-4 and APRI Index.

Page 8 of 13



Dr. SHWETA GUPTA MBBS, MD (Pathology) Consultant Pathology SIN No:SE04800630





: Mrs.RAJASHREE LAXMI

Age/Gender

Emp/Auth/TPA ID

: 37 Y 6 M 0 D/F

UHID/MR No Visit ID

: SCHI.0000022830

Ref Doctor

: Dr.SELF

: SCHIOPV34457

: hffdgujhg

Collected

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 06:28PM

Reported Status

: 03/Aug/2024 07:26PM

Sponsor Name

: Final Report : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology SIN No:SE04800630





: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F

UHID/MR No

: SCHI.0000022830

Visit ID Ref Doctor : SCHIOPV34457

Emp/Auth/TPA ID

: Dr.SELF : hffdgujhg Collected

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 06:28PM

Reported

: 03/Aug/2024 07:26PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED


DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
RENAL PROFILE/KIDNEY FUNCTION	TEST (RFT/KFT), SEF	RUM		
CREATININE	0.70	mg/dL	0.5-1.04	Creatinine amidohydrolase
UREA	14.10	mg/dL	15-36	Urease
BLOOD UREA NITROGEN	6.6	mg/dL	8.0 - 23.0	Calculated
URIC ACID	4.70	mg/dL	2.5-6.2	Uricase
CALCIUM	8.00	mg/dL	8.4 - 10.2	Arsenazo-III
PHOSPHORUS, INORGANIC	4.00	mg/dL	2.5-4.5	PMA Phenol
SODIUM	139	mmol/L	135-145	Direct ISE
POTASSIUM	5.2	mmol/L	3.5-5.1	Direct ISE
CHLORIDE	108	mmol/L	98 - 107	Direct ISE
PROTEIN, TOTAL	6.90	g/dL	6.3-8.2	Biuret
ALBUMIN	4.50	g/dL	3.5 - 5	Bromocresol Green
GLOBULIN	2.40	g/dL	2.0-3.5	Calculated
A/G RATIO	1.88		0.9-2.0	Calculated

Page 10 of 13









: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F

UHID/MR No Visit ID

: SCHI.0000022830

Ref Doctor

: SCHIOPV34457

Emp/Auth/TPA ID

: Dr.SELF : hffdgujhg Collected

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 06:28PM

Reported

Status

: 03/Aug/2024 07:26PM

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GAMMA GLUTAMYL TRANSPEPTIDASE (GGT) , SERUM	10.00	U/L	12-43	Glyclyclycine Nitoranalide

Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology

SIN No:SE04800630

Page 11 of 13







: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F

UHID/MR No Visit ID : SCHI.0000022830

Ref Doctor

: SCHIOPV34457 : Dr.SELF

Emp/Auth/TPA ID : hffdgujhg

Collected

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 07:44PM

Reported

: 03/Aug/2024 09:06PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method			
THYROID PROFILE TOTAL (T3, T4, TSH), SERUM							
TRI-IODOTHYRONINE (T3, TOTAL)	1.02	ng/mL	0.87-1.78	CLIA			
THYROXINE (T4, TOTAL)	9.4	μg/dL	5.48-14.28	CLIA			
THYROID STIMULATING HORMONE (TSH)	3.136	μIU/mL	0.38-5.33	CLIA			

Comment:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 - 3.0

- **1.** TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- **2.** TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- **3.** Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.
- **4.** Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	T3	T4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes

Page 12 of 13

Dr.Tanish Mandal M.B.B.S,M.D(Pathology) Consultant Pathologist SIN No:SPL24128160









: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F : SCHI.0000022830

UHID/MR No Visit ID

. 00111.0000002200

Ref Doctor

: SCHIOPV34457

Emp/Auth/TPA ID

: Dr.SELF : hffdgujhg Collected

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 07:44PM

Reported

: 03/Aug/2024 09:06PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY


ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma	
------	------	------	------	--	--

*** End Of Report ***

Page 13 of 13









: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F : SCHI.0000022830

UHID/MR No Visit ID

: SCHIOPV34457

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : hffdgujhg Collected

: 03/Aug/2024 05:11PM

Received Reported : 03/Aug/2024 05:38PM : 03/Aug/2024 07:25PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

PERIPHERAL SMEAR, WHOLE BLOOD EDTA

Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology SIN No:BED240203993



Page 1 of 13





: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F

UHID/MR No

: SCHI.0000022830

Visit ID

: SCHIOPV34457

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : hffdgujhg Collected

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 05:38PM

Reported

Status

: 03/Aug/2024 07:25PM

Sponsor Name

: Final Report

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
HEMOGRAM , WHOLE BLOOD EDTA				
HAEMOGLOBIN	13.4	g/dL	12-15	CYANIDE FREE COLOUROMETER
PCV	41.20	%	40-50	PULSE HEIGHT AVERAGE
RBC COUNT	6.03	Million/cu.mm	3.8-4.8	Electrical Impedence
MCV	68.4	fL	83-101	Calculated
MCH	22.2	pg	27-32	Calculated
MCHC	32.4	g/dL	31.5-34.5	Calculated
R.D.W	17.2	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	8,250	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT	(DLC)			
NEUTROPHILS	61.7	%	40-80	Electrical Impedance
LYMPHOCYTES	29.4	%	20-40	Electrical Impedance
EOSINOPHILS	2.8	%	1-6	Electrical Impedance
MONOCYTES	5.5	%	2-10	Electrical Impedance
BASOPHILS	0.6	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	5090.25	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	2425.5	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	231	Cells/cu.mm	20-500	Calculated
MONOCYTES	453.75	Cells/cu.mm	200-1000	Calculated
BASOPHILS	49.5	Cells/cu.mm	0-100	Calculated
Neutrophil lymphocyte ratio (NLR)	2.1		0.78- 3.53	Calculated
PLATELET COUNT	193000	cells/cu.mm	150000-410000	IMPEDENCE/MICROSCOPY
ERYTHROCYTE SEDIMENTATION RATE (ESR)	08	mm at the end of 1 hour	0-20	Modified Westergren
PERIPHERAL SMEAR				

RBCs ARE NORMOCYTIC NORMOCHROMIC.

TLC, DLC WITHIN NORMAL LIMIT. NO IMMATURE CELLS ARE SEEN. PLATELETS ARE ADEQUATE.

Page 2 of 13



Dr. SHWETA GUPTA MBBS, MD (Pathology) Consultant Pathology SIN No:BED240203993





: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F : SCHI.0000022830

UHID/MR No Visit ID

: SCHIOPV34457

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : hffdgujhg

Collected

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 05:38PM

Reported

: 03/Aug/2024 07:25PM

Status : Final Report Sponsor Name : ARCOFEMI F

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

NO HEMOPARASITES SEEN

Page 3 of 13







: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F

UHID/MR No

: SCHI.0000022830

Visit ID Ref Doctor : SCHIOPV34457

Emp/Auth/TPA ID

: Dr.SELF : hffdgujhg Collected

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 05:38PM

Reported

: 03/Aug/2024 09:56PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
BLOOD GROUP ABO AND RH FACTOR	R, WHOLE BLOOD EDTA		<u>'</u>	<u>'</u>
BLOOD GROUP TYPE	В			Forward & Reverse Grouping with Slide/Tube Aggluti
Rh TYPE	POSITIVE			Forward & Reverse Grouping with Slide/Tube Agglutination

Page 4 of 13









: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F

UHID/MR No Visit ID

: SCHI.0000022830

Ref Doctor

: SCHIOPV34457 : Dr.SELF

: hffdgujhg

Emp/Auth/TPA ID

Collected

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 06:30PM

Reported Status

: 03/Aug/2024 07:14PM

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GLUCOSE, FASTING, NAF PLASMA	101	mg/dL	70-100	GOD - POD

Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

Page 5 of 13











: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F

UHID/MR No

: SCHI.0000022830

Visit ID

: SCHIOPV34457

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : hffdgujhg Collected

Status

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 07:44PM

Reported

: 03/Aug/2024 10:15PM

Sponsor Name

: Final Report

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method	
HBA1C (GLYCATED HEMOGLOBIN), WHOLE BLOOD EDTA					
HBA1C, GLYCATED HEMOGLOBIN	5.7	%		HPLC	
ESTIMATED AVERAGE GLUCOSE (eAG)	117	mg/dL		Calculated	

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %
NON DIABETIC	<5.7
PREDIABETES	5.7 - 6.4
DIABETES	≥ 6.5
DIABETICS	
EXCELLENT CONTROL	6 – 7
FAIR TO GOOD CONTROL	7 - 8
UNSATISFACTORY CONTROL	8 - 10
POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic

Control by American Diabetes Association guidelines 2023.

- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control

A: HbF >25%

B: Homozygous Hemoglobinopathy.

(Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 6 of 13



Dr Nidhi Sachdev M.B.B.S, MD(Pathology) Consultant Pathologist

SIN No:EDT240083866





: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F

UHID/MR No

: SCHI.0000022830

Visit ID Ref Doctor : SCHIOPV34457

Emp/Auth/TPA ID

: Dr.SELF : hffdgujhg Collected

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 06:28PM

Reported

Status

: 03/Aug/2024 07:26PM

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
LIPID PROFILE, SERUM	'			<u>'</u>
TOTAL CHOLESTEROL	128	mg/dL	<200	CHE/CHO/POD
TRIGLYCERIDES	80	mg/dL	<150	Enzymatic
HDL CHOLESTEROL	47	mg/dL	>40	CHE/CHO/POD
NON-HDL CHOLESTEROL	81	mg/dL	<130	Calculated
LDL CHOLESTEROL	65	mg/dL	<100	Calculated
VLDL CHOLESTEROL	16	mg/dL	<30	Calculated
CHOL / HDL RATIO	2.72		0-4.97	Calculated
ATHEROGENIC INDEX (AIP)	0.02		<0.11	Calculated

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

Measurements in the same patient can show physiological and analytical variations.

NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.

Page 7 of 13



SIN No:SE04800630





: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F

UHID/MR No

: SCHI.0000022830

Visit ID Ref Doctor : SCHIOPV34457

Emp/Auth/TPA ID

: Dr.SELF : hffdgujhg Collected

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 06:28PM

Reported

Status

: 03/Aug/2024 07:26PM

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
LIVER FUNCTION TEST (LFT), SERUM				
BILIRUBIN, TOTAL	0.30	mg/dL	0.20-1.30	DIAZO METHOD
BILIRUBIN CONJUGATED (DIRECT)	0.10	mg/dL	0.0-0.3	Calculated
BILIRUBIN (INDIRECT)	0.20	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	12	U/L	<35	Visible with P-5-P
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	26.0	U/L	14-36	UV with P-5-P
AST (SGOT) / ALT (SGPT) RATIO (DE RITIS)	2.2		<1.15	Calculated
ALKALINE PHOSPHATASE	96.00	U/L	38-126	p-nitrophenyl phosphate
PROTEIN, TOTAL	6.90	g/dL	6.3-8.2	Biuret
ALBUMIN	4.50	g/dL	3.5 - 5	Bromocresol Green
GLOBULIN	2.40	g/dL	2.0-3.5	Calculated
A/G RATIO	1.87		0.9-2.0	Calculated

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin) Common patterns seen:

- 1. Hepatocellular Injury:
- *AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal *ALT – Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI. Disproportionate increase in AST, ALT compared with ALP. AST: ALT (ratio) – In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.
- 2. Cholestatic Pattern:
- *ALP Disproportionate increase in ALP compared with AST, ALT. ALP elevation also seen in pregnancy, impacted by age *Bilirubin elevated- predominantly direct, To establish the hepatic origin correlation with elevated GGT helps. and sex.
- 3. Synthetic function impairment:
- *Albumin-Liver disease reduces albumin levels, Correlation with PT (Prothrombin Time) helps.
- 4. Associated tests for assessment of liver fibrosis Fibrosis-4 and APRI Index.

Page 8 of 13



Dr. SHWETA GUPTA MBBS, MD (Pathology) Consultant Pathology SIN No:SE04800630





: Mrs.RAJASHREE LAXMI

Age/Gender

Emp/Auth/TPA ID

: 37 Y 6 M 0 D/F

UHID/MR No Visit ID

: SCHI.0000022830

Ref Doctor

: Dr.SELF

: SCHIOPV34457

: hffdgujhg

Collected

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 06:28PM

Reported Status

: 03/Aug/2024 07:26PM

Sponsor Name

: Final Report : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology SIN No:SE04800630





: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F

UHID/MR No

: SCHI.0000022830

Visit ID Ref Doctor : SCHIOPV34457

Emp/Auth/TPA ID

: Dr.SELF : hffdgujhg Collected

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 06:28PM

Reported

: 03/Aug/2024 07:26PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED


DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
RENAL PROFILE/KIDNEY FUNCTION	TEST (RFT/KFT), SEF	RUM		
CREATININE	0.70	mg/dL	0.5-1.04	Creatinine amidohydrolase
UREA	14.10	mg/dL	15-36	Urease
BLOOD UREA NITROGEN	6.6	mg/dL	8.0 - 23.0	Calculated
URIC ACID	4.70	mg/dL	2.5-6.2	Uricase
CALCIUM	8.00	mg/dL	8.4 - 10.2	Arsenazo-III
PHOSPHORUS, INORGANIC	4.00	mg/dL	2.5-4.5	PMA Phenol
SODIUM	139	mmol/L	135-145	Direct ISE
POTASSIUM	5.2	mmol/L	3.5-5.1	Direct ISE
CHLORIDE	108	mmol/L	98 - 107	Direct ISE
PROTEIN, TOTAL	6.90	g/dL	6.3-8.2	Biuret
ALBUMIN	4.50	g/dL	3.5 - 5	Bromocresol Green
GLOBULIN	2.40	g/dL	2.0-3.5	Calculated
A/G RATIO	1.88		0.9-2.0	Calculated

Page 10 of 13









: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F

UHID/MR No Visit ID

: SCHI.0000022830

Ref Doctor

: SCHIOPV34457

Emp/Auth/TPA ID

: Dr.SELF : hffdgujhg Collected

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 06:28PM

Reported

Status

: 03/Aug/2024 07:26PM

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method	
GAMMA GLUTAMYL TRANSPEPTIDASE (GGT) , SERUM	10.00	U/L	12-43	Glyclyclycine Nitoranalide	

Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology

SIN No:SE04800630

Page 11 of 13







: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F

UHID/MR No Visit ID : SCHI.0000022830

Ref Doctor

: SCHIOPV34457 : Dr.SELF

Emp/Auth/TPA ID : hffdgujhg

Collected

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 07:44PM

Reported

: 03/Aug/2024 09:06PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
THYROID PROFILE TOTAL (T3, T4, TSF	l), SERUM			
TRI-IODOTHYRONINE (T3, TOTAL)	1.02	ng/mL	0.87-1.78	CLIA
THYROXINE (T4, TOTAL)	9.4	μg/dL	5.48-14.28	CLIA
THYROID STIMULATING HORMONE (TSH)	3.136	μIU/mL	0.38-5.33	CLIA

Comment:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)			
First trimester	0.1 - 2.5			
Second trimester	0.2 - 3.0			
Third trimester	0.3 - 3.0			

- **1.** TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- **2.** TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- **3.** Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.
- **4.** Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	T3	T4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes

Page 12 of 13

Dr.Tanish Mandal M.B.B.S,M.D(Pathology) Consultant Pathologist

SIN No:SPL24128160









: Mrs.RAJASHREE LAXMI

Age/Gender

: 37 Y 6 M 0 D/F : SCHI.0000022830

UHID/MR No Visit ID

. 00111.0000002200

Ref Doctor

: SCHIOPV34457

Emp/Auth/TPA ID

: Dr.SELF : hffdgujhg Collected

: 03/Aug/2024 05:11PM

Received

: 03/Aug/2024 07:44PM

Reported

: 03/Aug/2024 09:06PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma	
------	------	------	------	--	--

*** End Of Report ***

Page 13 of 13



